Table 2.
Tal1/Lmo2 tumors are immunophenotypically heterogeneous
| Animal no. | Genotype | Phenotype | % DN | DN subtype | Latency |
|---|---|---|---|---|---|
| 1001 | Tal1/Lmo2 5 | DP, CD8SP | 20 | DN3 | 91 |
| 1002 | Tal1/Lmo2 5 | DP, DN | 58 | DN3,4 | 93 |
| 1004 | Tal1/Lmo2 5 | CD8SP | 16 | DN3 | 91 |
| 1007 | Tal1/Lmo2 5 | DP, CD8SP | 18 | DN3 | 124 |
| 1078 | Tal1/Lmo2 5 | CD8SP, DN | 21 | DN3,4 | 100 |
| 1099 | Tal1/Lmo2 5 | DP, DN | 35.9 | DN3,4 | 101 |
| 8115 | Tal1/Lmo2 5 | DP, DN | 27.2 | DN3 | 89 |
| 8129 | Tal1/Lmo2 5 | DP | 2.83 | DN2 (3) | 128 |
| 8159 | Tal1/Lmo2 5 | CD4SP, DN | 20 | ND | 93 |
| 8164 | Tal1/Lmo2 5 | All CD8SP-DN | DN2 | 161 | |
| 8179 | Tal1/Lmo2 5 | DP | 3.15 | DN1,2,3,4 | 119 |
| 8181 | Tal1/Lmo2 5 | DP, DN | 72 | DN3 | 212 |
| 8308 | Tal1/Lmo2 5 | DP, CD8SP | 1.2 | DN4 | 60 |
| 8361 | Tal1/Lmo2 5 | DP | 4 | DN3,4 | 145 |
| 8382 | Tal1/Lmo2 19 | DP, DN | 40 | DN3,4 | 111 |
| 8383 | Tal1/Lmo2 19 | CD8SP | 4.6 | DN3, 4 | 135 |
| 8602 | Tal1/Lmo2 5 | DP, DN, CD8SP | 40 | DN2 (3,4) | 88 |
| 8613 | Tal1/Lmo2 5 | DP | 3 | DN3,4 | 120 |
| 8647 | Tal1/Lmo2 5 | DP | 6 | DN4 | 109 |
| 8653 | Tal1/Lmo2 5 | DP | 4 | DN3 | 109 |
| 8655 | Tal1/Lmo2 5 | DP, CD8SP | 2.73 | DN3,4 | ND |
| 8683 | Tal1/Lmo2 5 | DP | 15.8 | DN1,2 | 109 |
| 8734 | Tal1/Lmo2 19 | DP, CD8SP | 4 | ND | 135 |
| 8757 | Tal1/Lmo2 5 | DP | 19 | DN3,4 | 112 |
| 9053 | Tal1/Lmo2 19 | DP | 6 | DN3,4 | 109 |
ND indicates not determined.
Tumors were designated positive if > 20% of the cells expressed the marker(s).